曲美他嗪对冠状动脉介入术后患者心绞痛发作频率及运动耐量的影响  

Effects of trimetazidine on angina frequency and exercise tolerance in patients undergoing percutaneous coronary intervention

作　　者：李潞[1] 赵红丽[1] 张晓丹[1] 谭力力[1] 周杨[1] 

机构地区：[1]沈阳医学院附属沈洲医院,辽宁沈阳110002

出　　处：《中国心血管杂志》2008年第3期205-208,共4页Chinese Journal of Cardiovascular Medicine

摘　　要：目的评价曲美他嗪对冠状动脉介入术后患者心绞痛发作频率及运动耐量的影响。方法首次冠状动脉介入治疗患者112例,分为曲美他嗪组以及常规治疗组,各56例。所有患者每月门诊随访1次,共6个月,记录心绞痛发作次数、每次发作持续时间、硝酸甘油的应用、心绞痛CCS分级,主要心脏不良事件(MACE)发生情况;并于开始治疗前以及药物治疗6个月后,行超声心动图检查及6min步行试验。结果两组患者MACE发生率差异无统计学意义(曲美他嗪组:8.9%,常规治疗组:10.7%)(P>0.05);在心绞痛发作例数、心绞痛发作次数、发作持续时间、心绞痛CCSⅢ级,发作时需用硝酸甘油缓解例数方面曲美他嗪组均少于常规治疗组(P均<0.05)。在治疗开始两组患者LVEF及6min步行距离差异无统计学意义(P均>0.05);治疗6个月后曲美他嗪组LVEF及6min步行距离较前显著改善(P均<0.05);且6min步行距离较常规治疗组明显增加(P<0.05)。结论冠状动脉介入术后常规加用曲美他嗪可以减少心绞痛发作,改善左心功能,提高运动耐量。Objective To investigate the effects of trimetazidine on angina frequency and exercise tolerance in patients undergoing percutaneous coronary intervention. Methods A total of 112 patients treated with PCI were selected randomly to trimetazidine group and routine therapy group, and were followed up for 6 months. Angina frequency, angina duration, number of CCS Ⅲ class, consumption of nitroglycerol and major adverse cardiac events （MACE） were recorded. 2-dimensional echocardiography （2DE） and 6-mintute walk test were performed in all patients at baseline and 6 months after PCI. Results No difference of MACE was found in two groups. Angina frequency, angina duration, CCS Ⅲ class, need of nitroglycerol were all significantly reduced in trimetazidine group compared to routine therapy group （P〈0.05）. LVEF and mean distance of 6-mintute walk test were significantly increased in trimetazidine group after 6 months than those at baseline （P〈0.05）. Mean distance of 6-mintute walk test was longer in trimetazidine group than that in routine therapy group （P〈0.05）. Conclusions Trimetazidine therapy can reduce angina frequency and increase exercise tolerance in post PCI patients.

关 键 词：曲美他嗪 血管成形术 经腔 经皮冠状动脉 心绞痛 

分 类 号：R541.4[医药卫生—心血管疾病]